320 related articles for article (PubMed ID: 26683226)
21. Low spinophilin expression enhances aggressive biological behavior of breast cancer.
Schwarzenbacher D; Stiegelbauer V; Deutsch A; Ress AL; Aigelsreiter A; Schauer S; Wagner K; Langsenlehner T; Resel M; Gerger A; Ling H; Ivan C; Calin GA; Hoefler G; Rinner B; Pichler M
Oncotarget; 2015 May; 6(13):11191-202. PubMed ID: 25857299
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
[TBL] [Abstract][Full Text] [Related]
23. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
24. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
Du T; Song Y; Ray A; Chauhan D; Anderson KC
Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294
[TBL] [Abstract][Full Text] [Related]
25. MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer.
Nikpour M; Emadi-Baygi M; Fischer U; Niegisch G; Schulz WA; Nikpour P
Urol Oncol; 2014 Jul; 32(5):670-7. PubMed ID: 24495449
[TBL] [Abstract][Full Text] [Related]
26. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
Kobayashi T; Kuroda J; Ashihara E; Oomizu S; Terui Y; Taniyama A; Adachi S; Takagi T; Yamamoto M; Sasaki N; Horiike S; Hatake K; Yamauchi A; Hirashima M; Taniwaki M
Leukemia; 2010 Apr; 24(4):843-50. PubMed ID: 20200560
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway.
Zou Y; Qin X; Xiong H; Zhu F; Chen T; Wu H
Tumour Biol; 2015 Jul; 36(7):5187-93. PubMed ID: 25652471
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
[TBL] [Abstract][Full Text] [Related]
29. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
30. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.
Kelly KR; Espitia CM; Zhao W; Wendlandt E; Tricot G; Zhan F; Carew JS; Nawrocki ST
Oncotarget; 2015 Dec; 6(38):41275-89. PubMed ID: 26513296
[TBL] [Abstract][Full Text] [Related]
31. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha MN; Abdi J; Yang Y; Chang H
Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
[TBL] [Abstract][Full Text] [Related]
32. FOXM1 is a therapeutic target for high-risk multiple myeloma.
Gu C; Yang Y; Sompallae R; Xu H; Tompkins VS; Holman C; Hose D; Goldschmidt H; Tricot G; Zhan F; Janz S
Leukemia; 2016 Apr; 30(4):873-82. PubMed ID: 26648534
[TBL] [Abstract][Full Text] [Related]
33. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
Yang L; Tian Y; Leong WS; Song H; Yang W; Wang M; Wang X; Kong J; Shan B; Song Z
Breast Cancer Res; 2018 Sep; 20(1):113. PubMed ID: 30227879
[TBL] [Abstract][Full Text] [Related]
34. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
35. Repression of metadherin inhibits biological behavior of prostate cancer cells and enhances their sensitivity to cisplatin.
Wei YB; Guo Q; Gao YL; Yan B; Wang Z; Yang JR; Liu W
Mol Med Rep; 2015 Jul; 12(1):226-32. PubMed ID: 25684730
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
37. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
39. Discovery platform for inhibitors of IgH gene enhancer activity.
Dolloff NG
Cancer Biol Ther; 2019; 20(4):571-581. PubMed ID: 30481117
[TBL] [Abstract][Full Text] [Related]
40. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
